Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)-Reference-Cited by-同舟云学术

Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)

Published:2022-07 Issue:7 Volume:23 Page:899-909
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Agarwal Neeraj,McGregor Bradley,Maughan Benjamin L,Dorff Tanya B,Kelly William,Fang Bruno,McKay Rana R,Singh Parminder,Pagliaro Lance,Dreicer Robert,Srinivas Sandy,Loriot Yohann,Vaishampayan Ulka,Goel Sanjay,Curran Dominic,Panneerselvam Ashok,Schwickart Martin,Choueiri Toni K,Pal Sumanta

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. Metastatic prostate cancer;Sartor;N Engl J Med,2018

2. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer;Halabi;J Clin Oncol,2016

3. Evolving natural history of metastatic prostate cancer;Nafissi;Cureus,2020

4. Progressive site-directed therapy for castration-resistant prostate cancer: localization of the progressive site as a prognostic factor;Yoshida;Int J Radiat Oncol Biol Phys,2019

5. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth;Yakes;Mol Cancer Ther,2011

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer;Investigational New Drugs;2024-08-21

2. A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer;ESMO Open;2024-06

3. From biology to the clinic — exploring liver metastasis in prostate cancer;Nature Reviews Urology;2024-04-26

4. Targeting the tumor microenvironment, a new therapeutic approach for prostate cancer;Prostate Cancer and Prostatic Diseases;2024-04-02

5. The more the merrier? Evidence and efficacy of immune checkpoint- and tyrosine kinase inhibitor combinations in advanced solid cancers;Cancer Treatment Reviews;2024-04